Compare McKesson Corporation (MCK) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Vanguard Total World Stock Index Fund ETF — how do they compare? McKesson Corporation trades at $824.42 (market cap $97.35B), while Vanguard Total World Stock Index Fund ETF trades at $156.21. The key difference: McKesson Corporation pays a 0.39% dividend while Vanguard Total World Stock Index Fund ETF pays none, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | VT | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $995.69 | $159.35 |
52-Week Low | $659.01 | $128.41 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
VT trades at $154.29, down 0.32% on the day, with technical indicators signaling a bearish trend amid neutral oscillators. The ETF's broad global diversification and low expense ratio of 0.06% are key strengths, though financial ratios are not disclosed in the provided data. Recent news highlights comparisons with competing international ETFs, emphasizing VT's comprehensive market exposure.
The outlook remains cautious due to bearish technical signals and competitive pressures from lower-cost alternatives. Risks include expense ratio disadvantages versus peers and global market volatility. Analyst sentiment is mixed, with ongoing debates about optimal international ETF selection influencing investor positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
